People: Axcella Health Inc (AXLA.OQ)
24 Feb 2020
Dr. Catherine Angell Sohn is Independent Director of the Company. Dr. Sohn held a series of leadership positions in strategic product and business development and commercial operating roles at GlaxoSmithKline plc and its predecessor companies, SmithKline Beecham and SK&F, most recently as Senior Vice President until 2010. She currently serves on the board of directors of Jazz Pharmaceuticals plc, a public commercial-stage biopharmaceutical company, Rubius Therapeutics, Inc., a public clinical-stage biopharmaceutical company and Landec Corporation, a public company with two divisions, a contract development and manufacturing organization and a natural food company. Dr. Sohn also is Chairman of BioEclipse Therapeutics, a private clinical stage biotechnology company. As an independent Director, Dr. Sohn has served as Chair of Nominating / Corporate Governance and Compensations Committees and as a member on Audit Committees. She previously served on the board of Neuralstem, Inc., a public biopharmaceutical company until 2017. Dr. Sohn received a Pharm.D. from the University of California, San Francisco, a certificate in professional development from the Wharton School at the University of Pennsylvania and is a NACD (National Association of Corporate Directors) Board Leadership Fellow.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|